Pooja Ghatalia is an Oncology physician affiliated with Fox Chase Cancer Center. OpenAlex indexes 289 publications with 2,940 citations (h-index 28); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
333 Cottman Ave
Philadelphia, PA 19111
Telephone
215-728-2500Registry record last updated 29 Jun 2018.
Clinical trials
- Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
Sponsor: Fox Chase Cancer Center
- Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Sponsor: Fox Chase Cancer Center
- A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
Sponsor: Fox Chase Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- Merck Sharp & Dohme LLCProgram year20232 payments
- Eisai Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
62.6%Cytochrome P450 17A1 Inhibitor20.1%Abiraterone Acetate100%Part D≥27 patientsGonadotropin Releasing Hormone Receptor Antagonist15.7%Orgovyx100%Part D≥30 patients+ 4 more classes in this area
Metabolism & gastrointestinal
20%Corticosteroid15%Prednisone100%Part D≥28 patientsSerotonin-3 Receptor Antagonist3.2%Ondansetron Hcl100%Part D≥18 patients+ 1 more class in this area
Nervous system
7.2%Gabapentinoids3.4%Gabapentin100%Part D<11 patientsPhenothiazine2.1%Prochlorperazine Maleate100%Part D≥15 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).
Journal of Clinical Oncology
2025 - Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Elizabeth Plimack, MD
Fox Chase Cancer Center
Robert Uzzo, MD02041967
Fox Chase Cancer Center
John Ridge, MD
Fox Chase Cancer Center
Eric Horwitz, MD
Fox Chase Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”